Dive Brief:
Treatment with a repurposed arthritis drug from Eli Lilly and Incyte did not significantly lessen the risk of worsening disease among people hospitalized with COVID-19, the company announced Thursday, citing results from an international study of some 1,500 volunteers.
In a somewhat paradoxical result, however, Lilly said its drug, called baricitinib and sold as Olumiant for rheumatoid arthritis, substantially reduced the risk of death by any cause in the trial, which compared the oral medicine to placebo when given on top of standard COVID-19 treatments like steroids and Gilead s Veklury.
Roughly 8% of study participants given baricitinib along with standard care died by day 28 of the trial versus 13.1% who received placebo, a reduction of 38%. Researchers observed a benefit regardless of how sick volunteers were at the beginning of the study, Lilly said, and in pre-specified subgroups who were treated with or without steroids at the trial s start.
Tsunami of Chronic Health Conditions Expected, Research & Health Care Disrupted
By: Journal Reports, AHA
A tsunami of chronic health conditions as a result of the SARS-CoV-2 pandemic, especially cardiometabolic disease, may produce an enormous wave of death and disability that demands immediate, comprehensive strategies. In addition, COVID-19 has disrupted cardiovascular science and medicine, yet it presents opportunities to transform and create novel approaches that can yield new successes. These are the opinions of two esteemed leaders in cardiovascular disease care, research and strategy, detailed in two new Frame of Reference articles published today in the American Heart Association’s flagship journal
Expert calls for swift action to avoid chronic health conditions caused by COVID-19
A tsunami of chronic health conditions as a result of the SARS-CoV-2 pandemic, especially cardiometabolic disease, may produce an enormous wave of death and disability that demands immediate, comprehensive strategies.
In addition, COVID-19 has disrupted cardiovascular science and medicine, yet it presents opportunities to transform and create novel approaches that can yield new successes. These are the opinions of two esteemed leaders in cardiovascular disease care, research and strategy, detailed in two new Frame of Reference articles published today in the American Heart Association s flagship journal
Circulation.
Tsunami of Chronic Health Conditions Expected Due to COVID-19 Disruption of Healthcare
COVID-19 disrupted all aspects of science and medicine and unmasked striking disparities and opportunities for transformation
April 6, 2021 A tsunami of chronic health conditions as a result of the COVID-19 (SARS-CoV-2) pandemic, especially cardiometabolic disease, may produce an enormous wave of death and disability that demands immediate, comprehensive strategies. In addition, COVID-19 has disrupted cardiovascular science and medicine, yet it presents opportunities to transform and create novel approaches that can yield new successes. These are the opinions of two esteemed leaders in cardiovascular disease care, research and strategy, detailed in two new frame of reference articles published today in the American Heart Association (AHA) flagship journal
Traveling While Vaccinated: Expert Tips Before You Head Out medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.